Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that attacks the brain and results in impaired memory, thinking and behaviour in the elderly. This disease is pathologically characterized by the degeneration of the basal forebrain cholinergic system and the deposit of amyloid plaques in the brain (Whitehouse et al., 1982; Selkoe, 1991). It has become the fourth leading cause of death in developed nations. In the USA, the costs related to AD exceed those of related to cancer and heart disease. Yet, at present, there is no effective treatment available for this disorder.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Giacobini E and Becker R (1994): Development of drugs for Alzheimer therapy: a decade of progress. In: Alzheimer Therapy: Therapeutic Strategies. Giacobini E and Becker R eds. Boston: Birkhauser.
Darno P, Pomponi M, Giacobini E, Tang XC and Williams E (1989): The effect of heptyl-physostigmine, a new Cholinesterase inhibitor, on central cholinergic system of the rat. Neurochem Res 14: 971–997.
Hanin I (1990): In: Progress in Brain Research: Cholinergic Neurotransmission: Functional and Clinical Aspects, Vol 84, Aquilonius S-M and Gilberg P-G, eds. Amsterdam: Elsevier, pp. 289–299.
Hanin I, Tang XC and Kozikowski AP (1991): Clinical and preclinical studies with huperzine A. In: Cholinergic Basis for Alzheimer Therapy, Giacobini E and Becker R, eds. Boston: Birkhauser, pp. 305–313.
Knapp MJ, Knopman DS, Solomon PR, Pendleberg WW and Davis CS et al. (1994): A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. J Am Med Assoc 27: 985–989.
Liu JS, Zhu YL, Yu CM, Han YY and Wu FW et al. (1986): The structure of huperzine A and B, two new alkaloids exibiting marked anticholinesterase activity. Can J Chem 64: 837–839.
Selkoe DJ (1991): The molecular pathology of Alzheimer’s disease. Neuron 6: 487–498.
Tang XC, Xiong ZQ, Qian BC, Zhou ZF and Zhang LL (1994): Cognition improvement by oral huperzine A: a novel acetylcholinesterase inhibitor. In: Alzheimer Therapy: Theraputic Strategies, Giacobini E and Becker R, eds. Boston: Birkhauser, pp. 113–119.
Tang XC, Han YF, Chen X and Zhu XD (1986): Effects of huperzine A on learning and retrieval process of discrimination performance in rats. Acta Pharmacol Sin 7(6): 507–512.
Whitehouse PJ, Pricc DL, Struble RG, Clark AW and Coylc JT et al. (1982): Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 215: 1237–1239.
Xiong ZQ, Han YF and Tang XC. (1995): Huperzine A ameliorates the spatial working memory impairments induced by AF64A. Neuroreport 6: 2221–2224
Xu SS, Gao ZZ, Weng Z, Du ZM and Xu WA et al.(1995): Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacologica Sinica 16(5): 391–395.
Yeung OY and Han YF (1996): Reversal effects of Huperzine A and Tacrine on memory deficits in bilateral NBM lesioned rats. Soc for Neurosci Abst.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Han, Y., Tang, X. (1997). Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor. In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_36
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_36
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive